| abstract |
the present disclosure relates to innovative compounds of the formula ie pharmaceutically acceptable salts, solvates, salt solvates and prodrugs thereof, useful in prevention (eg delayed onset or reduced risk of development) and treatment (eg control, alleviation or delay of cancer progression, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, mouth cancer, esophageal cancer, gastric cancer, intestinal cancer, cancer colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer.The compounds of the disclosure are selective ep4 receptor antagonists and the useful treatment of several diseases that can be improved by blocking pge2-mediated signaling. |